Loading stock data…
Agenus Inc (AGEN)
$5.98-0.21 (-3.39%)
Market ClosedLast close Jul 24
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Agenus Inc. in the Healthcare sector is trading at $5.98 with a market capitalization of $136M. Wall Street consensus targets $30.00 (1 analysts), implying a +401.7% move over the next 12 months. The stock is currently 31% below its 52-week high of $8.70, remaining 61.2% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +401.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $33.74M↓ | $34.20M↑ | $30.23M↑ | $25.69M↑ | $24.07M |
| Gross Profit | $21.91M↓ | $26.69M↑ | $6.00M↑ | -$1.26M↓ | $2.41M |
| Operating Income | $15.05M↑ | $14.40M↑ | -$4.86M↑ | -$16.78M↓ | -$13.31M |
| Net Income | $39.23M↑ | -$10.58M↓ | $63.91M↑ | -$27.95M↓ | -$25.27M |
Peer Comparison
JNJUNHPFE
Fundamentals
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identificati...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$136.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-29.20%
Volume
Today's trading volume
1.19M
Recent News
Do Options Traders Know Something About Agenus Stock We Don't?
Investors need to pay close attention to AGEN stock based on the movements in the options market lately.
Agenus (AGEN) Could Be 83% Undervalued Following Phase 1b Data And Financing
Agenus (AGEN) is back in focus after reporting three year Phase 1b data for its BOT+BAL immunotherapy in refractory microsatellite stable metastatic colorectal cancer, alongside an oversubscribed private placement tied to its registrational ROBBIN trial. See our latest analysis for Agenus. The BOT+BAL data and oversubscribed financing come after a sharp shift in sentiment toward Agenus, with a 7 day share price return of 54.32% and a 30 day share price return of 67.79%, even as the 1 year...
AGEN Stock Jumps on Securing $340M Financing to Fund Strategic Pivot
Agenus surges after securing up to $340M in financing to fund its phase III ROBBIN colon cancer study and extend its cash runway if warrants are exercised.
Agenus stock doubles as biotech narrows Phase 3 bet
Agenus is redirecting its Phase 3 colon-cancer strategy. The biotech company said on July 13 that it will stop providing financial support for its BATTMAN study and make ROBBIN, a planned Phase 3 trial of BOT+BAL before colon-cancer surgery, its central development priority. The shift is backed by ...
Agenus (AGEN) Moves 82.7% Higher: Will This Strength Last?
Agenus (AGEN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.